Hindlimb paralytic effects of prodynorphin-derived peptides following spinal subarachnoid injection in rats

Joseph B. Long, Alberto Martinez-Arizala, Eddie E. Echevarria, Raymond E. Tidwell, John W. Holaday

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Dynorphin A-(1-17) acts through non-opioid mechanisms to produce dose-related neurological deficits following injection into the lumbar spinal subarachnoid space in rats. Hindlimb motor function was examined following subarachnoid injection of dynorphin A fragments and other opioid peptides derived from prodynorphin to establish: (1) which portion(s) of the dynorphin A molecule cause hindlimb motor dysfunction, and (2) whether these paralytic actions are shared by other opioids (dynorphin B, α-neo-endorphin, and β-neo-endorphin) derived from the same promolecule. To minimize the influence of enzymatic inactivation on relative bioactivities, peptides were coinjected with a combination of peptidase inhibitors previously shown to enhance the actions of dynorphin A fragments in vitro. Dynorphin A-(1-17) and -(2-17) produced dose-related neurological deficits with equal potencies and durations. Although without effect when injected alone, dynorphin A-(1-8), -(1-7) and -(3-8) caused transient motor dysfunction when co-injected with peptidase inhibitors. In contrast, dynorphin A-(1-6), -(1-5) and -(6-17) did not disrupt hindlimb motor function with or without peptidase inhibition. Dynorphin B, α-neo-endorphin also caused hindlimb dysfunction which was potentiated by peptidase inhibition. These deficits appeared to result from non-opioid actions of these three peptides, since they were not blocked by the opioid antagonist naloxone. Thus, the paralytic effects of dynorphin A: (1) result from non-opioid actions involving the 3-7 or 3-8 positions of the molecule, and (2) are shared by other prodynorphin-derived opioid peptides.

Original languageEnglish
Pages (from-to)45-54
Number of pages10
JournalEuropean Journal of Pharmacology
Volume153
Issue number1
DOIs
StatePublished - Aug 9 1988
Externally publishedYes

Fingerprint

Dynorphins
Spinal Injections
Hindlimb
Peptides
Endorphins
dynorphin (1-8)
Opioid Peptides
Protease Inhibitors
Peptide Hydrolases
Subarachnoid Space
Injections
Narcotic Antagonists
Naloxone
preproenkephalin
Opioid Analgesics

Keywords

  • (Paralysis, Injury, Intrathecal)
  • Dynorphin A
  • Dynorphin B
  • Opiate receptors
  • Peptidase
  • Spinal cord
  • α-neo-Endorphin
  • β-neo-Endorphin

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Hindlimb paralytic effects of prodynorphin-derived peptides following spinal subarachnoid injection in rats. / Long, Joseph B.; Martinez-Arizala, Alberto; Echevarria, Eddie E.; Tidwell, Raymond E.; Holaday, John W.

In: European Journal of Pharmacology, Vol. 153, No. 1, 09.08.1988, p. 45-54.

Research output: Contribution to journalArticle

Long, Joseph B. ; Martinez-Arizala, Alberto ; Echevarria, Eddie E. ; Tidwell, Raymond E. ; Holaday, John W. / Hindlimb paralytic effects of prodynorphin-derived peptides following spinal subarachnoid injection in rats. In: European Journal of Pharmacology. 1988 ; Vol. 153, No. 1. pp. 45-54.
@article{8a54c7b7d67f4765a31abcf07adbd0ff,
title = "Hindlimb paralytic effects of prodynorphin-derived peptides following spinal subarachnoid injection in rats",
abstract = "Dynorphin A-(1-17) acts through non-opioid mechanisms to produce dose-related neurological deficits following injection into the lumbar spinal subarachnoid space in rats. Hindlimb motor function was examined following subarachnoid injection of dynorphin A fragments and other opioid peptides derived from prodynorphin to establish: (1) which portion(s) of the dynorphin A molecule cause hindlimb motor dysfunction, and (2) whether these paralytic actions are shared by other opioids (dynorphin B, α-neo-endorphin, and β-neo-endorphin) derived from the same promolecule. To minimize the influence of enzymatic inactivation on relative bioactivities, peptides were coinjected with a combination of peptidase inhibitors previously shown to enhance the actions of dynorphin A fragments in vitro. Dynorphin A-(1-17) and -(2-17) produced dose-related neurological deficits with equal potencies and durations. Although without effect when injected alone, dynorphin A-(1-8), -(1-7) and -(3-8) caused transient motor dysfunction when co-injected with peptidase inhibitors. In contrast, dynorphin A-(1-6), -(1-5) and -(6-17) did not disrupt hindlimb motor function with or without peptidase inhibition. Dynorphin B, α-neo-endorphin also caused hindlimb dysfunction which was potentiated by peptidase inhibition. These deficits appeared to result from non-opioid actions of these three peptides, since they were not blocked by the opioid antagonist naloxone. Thus, the paralytic effects of dynorphin A: (1) result from non-opioid actions involving the 3-7 or 3-8 positions of the molecule, and (2) are shared by other prodynorphin-derived opioid peptides.",
keywords = "(Paralysis, Injury, Intrathecal), Dynorphin A, Dynorphin B, Opiate receptors, Peptidase, Spinal cord, α-neo-Endorphin, β-neo-Endorphin",
author = "Long, {Joseph B.} and Alberto Martinez-Arizala and Echevarria, {Eddie E.} and Tidwell, {Raymond E.} and Holaday, {John W.}",
year = "1988",
month = "8",
day = "9",
doi = "10.1016/0014-2999(88)90586-9",
language = "English",
volume = "153",
pages = "45--54",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Hindlimb paralytic effects of prodynorphin-derived peptides following spinal subarachnoid injection in rats

AU - Long, Joseph B.

AU - Martinez-Arizala, Alberto

AU - Echevarria, Eddie E.

AU - Tidwell, Raymond E.

AU - Holaday, John W.

PY - 1988/8/9

Y1 - 1988/8/9

N2 - Dynorphin A-(1-17) acts through non-opioid mechanisms to produce dose-related neurological deficits following injection into the lumbar spinal subarachnoid space in rats. Hindlimb motor function was examined following subarachnoid injection of dynorphin A fragments and other opioid peptides derived from prodynorphin to establish: (1) which portion(s) of the dynorphin A molecule cause hindlimb motor dysfunction, and (2) whether these paralytic actions are shared by other opioids (dynorphin B, α-neo-endorphin, and β-neo-endorphin) derived from the same promolecule. To minimize the influence of enzymatic inactivation on relative bioactivities, peptides were coinjected with a combination of peptidase inhibitors previously shown to enhance the actions of dynorphin A fragments in vitro. Dynorphin A-(1-17) and -(2-17) produced dose-related neurological deficits with equal potencies and durations. Although without effect when injected alone, dynorphin A-(1-8), -(1-7) and -(3-8) caused transient motor dysfunction when co-injected with peptidase inhibitors. In contrast, dynorphin A-(1-6), -(1-5) and -(6-17) did not disrupt hindlimb motor function with or without peptidase inhibition. Dynorphin B, α-neo-endorphin also caused hindlimb dysfunction which was potentiated by peptidase inhibition. These deficits appeared to result from non-opioid actions of these three peptides, since they were not blocked by the opioid antagonist naloxone. Thus, the paralytic effects of dynorphin A: (1) result from non-opioid actions involving the 3-7 or 3-8 positions of the molecule, and (2) are shared by other prodynorphin-derived opioid peptides.

AB - Dynorphin A-(1-17) acts through non-opioid mechanisms to produce dose-related neurological deficits following injection into the lumbar spinal subarachnoid space in rats. Hindlimb motor function was examined following subarachnoid injection of dynorphin A fragments and other opioid peptides derived from prodynorphin to establish: (1) which portion(s) of the dynorphin A molecule cause hindlimb motor dysfunction, and (2) whether these paralytic actions are shared by other opioids (dynorphin B, α-neo-endorphin, and β-neo-endorphin) derived from the same promolecule. To minimize the influence of enzymatic inactivation on relative bioactivities, peptides were coinjected with a combination of peptidase inhibitors previously shown to enhance the actions of dynorphin A fragments in vitro. Dynorphin A-(1-17) and -(2-17) produced dose-related neurological deficits with equal potencies and durations. Although without effect when injected alone, dynorphin A-(1-8), -(1-7) and -(3-8) caused transient motor dysfunction when co-injected with peptidase inhibitors. In contrast, dynorphin A-(1-6), -(1-5) and -(6-17) did not disrupt hindlimb motor function with or without peptidase inhibition. Dynorphin B, α-neo-endorphin also caused hindlimb dysfunction which was potentiated by peptidase inhibition. These deficits appeared to result from non-opioid actions of these three peptides, since they were not blocked by the opioid antagonist naloxone. Thus, the paralytic effects of dynorphin A: (1) result from non-opioid actions involving the 3-7 or 3-8 positions of the molecule, and (2) are shared by other prodynorphin-derived opioid peptides.

KW - (Paralysis, Injury, Intrathecal)

KW - Dynorphin A

KW - Dynorphin B

KW - Opiate receptors

KW - Peptidase

KW - Spinal cord

KW - α-neo-Endorphin

KW - β-neo-Endorphin

UR - http://www.scopus.com/inward/record.url?scp=0023735298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023735298&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(88)90586-9

DO - 10.1016/0014-2999(88)90586-9

M3 - Article

C2 - 2905665

AN - SCOPUS:0023735298

VL - 153

SP - 45

EP - 54

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -